Nano-X Imaging Secures 400 System Placements as Commercialization Inflection Point Nears
Q4 2025 Earnings Call, April 20, 2026
Nano-X Imaging is entering a fundamentally different phase of its commercial trajectory. The company has signed agreements for approximately 400 system deployments over the next two to three years, including a significant framework deal with Howard Technology Solutions for 300 units, marking what CEO Erez Meltzer calls "a fundamental shift in how we are poised to scale our business from providing our technology to deploying it in meaningful volume, shifting toward a growing CapEx portion." With 38 systems currently at various stages of deployment and another 15 expected to be installed in coming months as part of the Nanox Imaging Network, the company maintains its $35 million revenue target for 2026, though the exact timing of the ramp remains uncertain.
Howard Agreement Provides Scale, But Revenue Timing Remains Backend Loaded
The Howard Technology Solutions agreement represents the largest single deployment commitment Nano-X has secured to date. Under the framework, Howard is expected to deploy 300 Nanox.ARC systems over three years, with 60 indicated for the first year. The agreement comes alongside multiple smaller distribution deals totaling approximately 60 additional units, including partnerships with Imperial Imaging Technology, Integrity Imaging, Elite Surgical, and Digital X-Ray Imaging.
However, investors should temper near-term expectations. CFO Ran Daniel indicated that most of the revenue impact will materialize in the second half of 2026, noting "I don't think that they should expect a big ramp in the revenue in Q1." Meltzer emphasized that "most of the agreements were signed beginning of about a month or two after the RSNA and part of them also after the ECR," meaning the onboarding process is just beginning. The company's current revenue base remains early stage, and as management acknowledged, "part of this deployed base is not generating revenues" yet.
The pace of deployment continues to face external headwinds. Meltzer noted that "the pace of deployment continues to be influenced by various external processes, including import licenses, construction timelines, and regulatory requirements in certain markets." While not satisfied with the pace, management views this as the "current operating reality" of introducing new medical technology into healthcare systems.
Manufacturing Restructuring Aims to Improve Margins, But Comes With $17.5 Million Impairment
Nano-X is closing its chip manufacturing line in South Korea and downsizing its fabrication facilities in a restructuring plan designed to align manufacturing costs with its long-term financial model. The company is shifting production to established international partners, including CSEM in Switzerland, and plans to work through substantial existing emitter inventory before fully transitioning to the outsourced model.
The restructuring resulted in a non-cash impairment charge of $17.5 million in Q4 2025, primarily related to machinery and equipment on the chip manufacturing line. Ran Daniel indicated that additional restructuring expenses in 2026 will be "relatively minor" and "won't be material," though there may be some cash components.
The strategic rationale makes sense given the timing. Meltzer explained that "this fab was built during COVID when semiconductors were not necessarily available. So right now, we are rationalizing the situation where we have a sustainable supplier with a much lower cost of the chips that we do." The Korean facility will be converted to more of an R&D center for ceramic tubes and potentially other products.
Q4 Financials Show Modest Growth But Margin Pressure Persists
Fourth quarter 2025 revenue came in at $3.7 million, up 23 percent from $3.0 million in the prior year period. The increase was driven by $300,000 in higher teleradiology services revenue and $400,000 from the consolidation of Nanox Health IT following its November 19, 2025 acquisition. Imaging system revenue of $49,000 was down from $136,000 in the prior year period, while AI and software solutions revenue increased to $500,000 from $100,000, largely due to the Health IT contribution.
Gross loss on a GAAP basis was $3.6 million compared to $2.9 million in the prior year period. On a non-GAAP basis, gross loss was $1.2 million, representing a 32 percent gross loss margin, compared to a 9 percent gross loss margin in the prior year period. The teleradiology business showed continued profitability with non-GAAP gross profit of $1.5 million and a 48 percent margin, up from $1.1 million and 41 percent in the prior year. However, imaging systems generated a gross loss of $2.6 million on revenue of just $49,000, underscoring the early-stage nature of that business.
Operating expenses on a non-GAAP basis increased modestly. Research and development expenses declined to $4.8 million from $5.4 million, while sales and marketing expenses increased to $2.0 million from $900,000, reflecting increased commercialization efforts and participation in the RSNA conference. General and administrative expenses rose slightly to $6.0 million from $5.8 million.
The GAAP net loss for the quarter was $33.4 million, up significantly from $14.1 million in the prior year period, primarily due to the $17.5 million impairment charge. Non-GAAP net loss attributable to ordinary shares was $11.2 million compared to $10.0 million in the prior year period.
The company ended the quarter with $60 million in cash, cash equivalents, and marketable securities, up from $55.5 million at the end of Q3 2025. During Q4, the company raised $15.5 million net through the sale of approximately 4.2 million ordinary shares. The company had 69.6 million shares outstanding as of December 31, 2025, compared to 63.8 million a year earlier.
Nanox Imaging Network Targets Higher Margin Use Cases
The company is advancing its Nanox Imaging Network initiative, designed to build a network-based imaging services model in the United States targeting segments like workers' compensation and specialized care "where reimbursement dynamics may support higher per scan pricing." Under this model, Nano-X supports system deployment, maintenance, and connectivity while partners manage site operations and local engagement. The company is deploying systems across a number of U.S. sites under this model.
While management acknowledged the initiative is "still in the very early stage," they believe it "can become an important component of our long-term commercial strategy as the utilization increases and the model is further validated." This represents a potentially higher-margin pathway to market compared to traditional equipment sales, though execution risk remains substantial.
Clinical Validation and Regulatory Progress Continue
Nano-X achieved several regulatory milestones during the quarter and is building a clinical evidence base to support commercialization. The company received TAP2D clearance in the United States, which provides a 2D view image output for the Nanox.ARC system to enhance radiologist diagnostic confidence. The company also updated its AMAR approval in Israel based on its existing CE Mark, enabling use without the adjunctive-use limitation.
Removal of the adjunctive-use limitation in the United States remains a "key regulatory priority" that management believes "can expand our addressable market and support broader adoption." The company is also working to finalize its CE Mark submission for the Nanox.ARC in Europe, currently anticipated in 2026, though subject to change based on regulatory priorities.
On the clinical front, Cedars-Sinai Medical Center in Los Angeles is joining a trial studying Nanox.AI's aortic valve calcification measurement solution currently under development. An on-site evaluation of the model across approximately 600 retrospective cases "exceeded our expectations with six cases of severe classification identified and approximately 100 cases showing clinically relevant findings." The Cedars-Sinai team has expressed interest in collaboration on scientific publications based on these results.
The company also secured its first institutional review board approval for a clinical trial within the United States through its collaboration with MDS Wellness in Michigan. The trial will focus on lung cancer screening of high-risk patients and the applicability of Nanox.ARC technology.
At the European Congress of Radiology, Dr. Nogah Shabshin, the company's Chief Medical Officer, presented scientific work on lung cancer screening using the Nanox.ARC, showing that in the majority of patients, screening outcomes based on the lung-RADS category were similar when analyzing CT and digital tomosynthesis. Management stated this "further strengthens the applicability of the DTS as a potential addition to screening activities ramping up globally."
International Expansion Accelerates With Argentina and European Partnerships
Nano-X announced an exclusive distribution agreement with Intec SRL, a leading medical distributor in Argentina with more than 35 years of experience. Intec will oversee marketing, distribution, installation, and support for the Nanox.ARC system across the country, subject to obtaining required regulatory approvals. The partnership strengthens Nano-X's presence in Latin America and leverages Intec's established relationships with healthcare providers and nationwide service capabilities.
In Europe, the company continues to build momentum through partners and regional distributors. Management noted that over the past few quarters, they have announced multiple European collaborations, including in France, Romania, Czech Republic, and Serbia, alongside additional engagement in other European markets. At the European Congress of Radiology, Nano-X showcased the Nanox.ARC live in Europe for the first time and presented new clinical and AI data, with management noting that "engagement levels were high, reflecting growing awareness of the system's clinical value."
The company received the Newcomer award at ECR 2026, reflecting what management described as "the growing recognition of Nanox within the European radiology community." The company also received the Red Dot Award for Product Design 2026 for the Nanox.ARC X-ray system.
AI Business Shows Growth, Health IT Integration Progressing
The AI business continues to develop with new customers and expanded agreements. The acquisition of VasoHealthcare IT, completed November 19, 2025, and now operating as Nanox Health IT, contributed $400,000 in revenue during the quarter. Management indicated the integration is progressing well, with "several new customer agreements" signed since completion. The Health IT platform is expected to "enhance our ability to integrate into clinical workflow, expand customer cases access and support cross engagement across our ecosystems."
Management emphasized that "the rest of the organization is leveraging the Health IT team's expertise and market presence, particularly as it pertains to lead generation for the USARAD Nanox.AI and Nanox.ARC." This cross-selling potential represents a key strategic rationale for the acquisition.
At the World Conference of Osteoporosis, Nanox.AI bone solutions were featured, including updates from the ADOPT trial conducted across four NHS Trusts and led by the University of Oxford, as well as initial observations from collaboration with the Greek Air Force. The data showed "the clinical and economic benefits of AI-based opportunistic screening for routine CT exams."
OEM Development Pipeline Progresses With Multiple Industrial Partners
Nano-X continues advancing its technology pipeline with ongoing development of next-generation field emission X-ray sources and tube architecture. Recent progress includes improvements in emitter design and fabrication processes aimed at expanding chip lifetime and enhancing performance, development of micro-focus and multi-zone emitter configurations for applications such as semiconductor inspection, and continued advancement of the Nanox.MDX multisource tube platform enabling new system architectures for 3D imaging.
The company recently received a purchase order from a leading semiconductor equipment manufacturer for developmental emitters supporting advanced inspection applications. With Oak Ridge National Laboratory, a second round of prototyping is currently in progress. One global imaging component supplier has agreed to evaluate the company's micro-focus emitter technology and is preparing dedicated test infrastructure, while another major OEM continues to advance prototype development based on Nano-X's emitter design with validation activities ongoing.
Leadership Transition as Long-Serving CFO Departs
Ran Daniel is stepping down as CFO after five years with the company to explore other opportunities. He will remain through a transition period. Management noted that during his tenure, Daniel "played an important role in strengthening our financial discipline, supporting our transition to a public company, and building the financial and reporting infrastructure needed to support our long-term strategy." He also led capital raises that strengthened the balance sheet.
Guy Nathanzon will join as the new CFO effective August 1, 2026. Nathanzon brings extensive financial leadership experience with U.S. publicly traded companies, including several senior CFO and CEO roles in med-tech companies. His background includes capital raising, capital markets experience on both the sell-side and buy-side, M&A, and global financial operations. He previously served as CFO of Scopio Labs, a medical technology company developing an AI-based diagnostic platform, and most recently as CFO of Valens Semiconductor, a New York Stock Exchange listed company.
Direct Sales Organization Remains Lean Despite Growing Distribution Network
In response to an analyst question, Meltzer provided details on the U.S. commercial organization. The company has five direct salespeople under a Director of Sales "coming from one of the biggest distributors in the country with a lot of experience." In addition, the company has clinical education specialists whose role is to "go to the places that we have the systems installed, train the people, trying to get a better understanding of the referring physician who works with this site." Their job is to "build awareness around the site and what's the clinical value that can be added for other referring physicians."
The company has administration and operational staff including technical people handling installations, as well as people "doing the STR, like building the deal flow." Management is "in the process of adding another two people who would be responsible for the channel management" given that the company now has "almost 10 business partners" requiring "a lot of coordination, a lot of support." The company has an onboarding process for each partner that is "very methodological" including training and demo units. Several recently signed business partners already have "tens of meetings that already were arranged with the potential customers in order to expand and to fulfill what they are committed to in this agreement."
Nano-X Imaging Deep Dive
The medical imaging industry remains one of the most structurally defended markets in global healthcare. For decades, the triopoly of GE HealthCare, Siemens Healthineers, and Philips has effectively consolidated the hospital diagnostic chain through a combination of proprietary hardware, deeply integrated clinical software ecosystems, and comprehensive service contracts. Into this environment stepped Nano-X Imaging, promising a disruption of the fundamental X-ray source—moving from traditional heat-based thermionic emission to a proprietary cold cathode technology. As of April 2026, the company stands at a critical juncture where the narrative of revolutionary technology is colliding with the harsh realities of commercial scaling, supply chain transition, and institutional sales cycles.
The Structural Moat of Imaging Incumbents
To understand the challenge facing Nano-X, one must first recognize the nature of the incumbency. Hospitals and imaging centers do not purchase equipment based solely on the physics of the X-ray source. They purchase systems that are seamlessly interoperable with Picture Archiving and Communication Systems (PACS) and Radiology Information Systems (RIS). The value proposition of the major incumbents is not just the image quality, but the uptime, the global field service footprint, and the trust established over decades of clinical validation. When a hospital purchases a CT or mobile X-ray unit, they are entering a ten-to-fifteen-year relationship. Displacing this requires more than just a cheaper or novel X-ray tube; it requires a total service ecosystem that Nano-X has only begun to assemble.
The market for imaging is shifting rapidly, but perhaps not in the direction that favors pure-play hardware disruptors. GE HealthCare and its primary competitors have moved aggressively into artificial intelligence-driven diagnostic workflows. These incumbents are not just selling machines; they are selling the reduction of radiologist burnout through autonomous image optimization, automated cardiac scoring, and AI-enabled triage. By embedding these capabilities directly into the massive installed bases they already control, incumbents have effectively raised the bar for entry. A competitor cannot simply offer a cheaper tomosynthesis system; they must offer the same level of diagnostic sophistication and workflow automation that the current standard-bearers have spent years embedding into the clinical fabric.
The Nano-X Execution Reality
Nano-X Imaging has reached a stage in its lifecycle where the rhetoric of potential must be validated by units in the field. The company’s financial performance through the close of 2025 and into early 2026 reveals a persistent disconnect between the scale of its ambition and the rate of its market penetration. With trailing twelve-month revenue that remains modest and net losses that have widened due to significant restructuring and impairment charges related to its Korean manufacturing facilities, the company is demonstrating how difficult it is to transition from a venture-funded R&D project to a sustainable commercial enterprise.
The strategic shift to outsource production to third-party manufacturers, including the Swiss Center for Electronics and Microtechnology, is a pragmatic move to mitigate the capital-intensive nature of hardware manufacturing. However, this transition introduces its own execution risks. By relinquishing control over the core fabrication of its proprietary chips, Nano-X is betting that its intellectual property can be successfully ported to third-party lines without compromising quality or yield. Furthermore, the company’s reliance on third-party distribution partners to hit its deployment targets creates a reliance on external sales forces that lack the historical loyalty to the brand that direct sales teams have for legacy players. While the move to sign distribution agreements for hundreds of systems is a necessary step, the conversion of these contracts into revenue-generating, billable usage remains the primary bottleneck.
The AI Pivot and Competitive Positioning
Where Nano-X has arguably found more strategic footing is its pivot toward AI-based diagnostics. The acquisition of software and teleradiology assets acknowledges a reality that the market has known for some time: hardware is a commodity, while software and clinical insights are where the margins reside. By integrating Nanox.AI with its hardware platform, the company is attempting to create a verticalized offering that might appeal to underserved clinics. However, in this space, Nano-X is not competing against obsolete technology; it is competing against GE and Siemens, both of which have been aggressively acquiring and developing AI tools for years. These giants are using AI to defend their hardware moats, making it difficult for an under-resourced entrant to carve out a foothold based on diagnostic software alone.
The competitive threat from new entrants is real but takes a different form than Nano-X likely envisioned. The most credible disruptive pressure in the imaging space is not coming from other startups attempting to build new X-ray tubes, but from existing players in the AI-software space who are partnering with traditional hardware providers to layer diagnostic intelligence over existing, reliable machinery. When a diagnostic center can achieve high-end AI insights using a ten-year-old machine from a major manufacturer, the urgency to rip and replace that system with a Nano-X ARC unit diminishes significantly. This underscores the risk: if the hardware is not the primary value driver, the business model must be incredibly robust to overcome the inertia of current hospital procurement.
The Scorecard
Nano-X Imaging is a company that has successfully navigated the immense regulatory hurdles of the FDA and CE certification process, proving that its core cold cathode technology is clinically viable. This is no small feat. However, the company is now facing the "valley of death" common to medical device startups: the transition from regulatory clearance to institutional adoption. The financial burden of maintaining global operations, combined with the difficulty of breaking into the entrenched hospital procurement cycle, creates a high-risk profile. The decision to restructure manufacturing and focus on third-party production is a signal of a maturing business that has recognized the unsustainable nature of its initial capital-intensive approach, yet this pivot adds new layers of operational complexity and execution risk that the management team must now oversee.
The fundamental challenge for investors is whether the company can achieve sufficient scale before its balance sheet constraints force dilutive financing or strategic retrenchment. The move into teleradiology and AI is a necessary diversification, but these segments are increasingly commoditized and fiercely contested by much larger, better-funded incumbents. Success in this environment will require near-flawless execution of deployment targets and a rapid, sustained increase in utilization rates across its installed base. At this stage, the company remains a highly speculative entity where the valuation is predicated almost entirely on the future, rather than current, commercial reality.